Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
This study has been completed.
Study NCT00056173   Information provided by Lorus Therapeutics
First Received: March 6, 2003   Last Updated: January 4, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Renal Cell
Metastases, Neoplasm
Additional conditions recognized in this trial
Carcinoma
Neoplasm Metastasis
Neoplasms
More general conditions related to this trial
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
GTI-2040
Additional drug interventions recognized in this trial
Capecitabine
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Lorus Therapeutics
Wake Forest University
University of Chicago


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services